Invitation to iCMLf Forum for physicians attending ASH 2017
Each year The Max Foundation and the International CML Foundation come together during the American Society of Hematology (ASH) Meeting to host a forum for physicians treating chronic myeloid leukemia (CML) in low resource settings. The aim is to provide resources, share programmatic updates and enable robust discussions between leading CML experts and those treating the disease in low- and middle-income countries. This year’s forum will have a new component of small group discussions to allow for a more intimate question & answer session.
If you are a physician attending ASH this year, please join us at the iCMLf Forum for Physicians from Emerging Economic Regions, carried out in partnership with The Max Foundation, on Friday 8th December at 12.30pm. The iCMLf Forum is a unique experience to discuss and share experiences from all around the world. We hope to hear yours!
The 2017 Forum features ‘Perspectives on the Management of CML’ covering the topics of Molecular Monitoring for CML and Treatment Free Remission. Speakers include Dr. Susan Branford (Australia), Dr. Katia Pagnano (Brazil) and Dr. Susanne Saussele (Germany). This year, there is an expanded format for physicians from low- and middle-income countries to “Meet the Expert” at the end of the meeting. In the small group sessions, physicians will be able to hear from and chat with CML experts around the management of TKIs.
The iCMLf Forum for Physicians from Emerging Regions will be held:
12.30pm – 3:30 pm on Friday 8th December at the Doubletree Downtown Atlanta, Georgia, USA
If you are traveling to ASH this year, please consider joining this meeting. Feel free to share this email and the attached invitation with your colleagues. Please click here to reserve your place or for any queries please email melissa@cml-foundation.org.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
The Max Foundation Creates Subsidiary Organization, MaxAid, to Further Mission
Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.
The Max Foundation (Max) Expands Board and Global Team to Advance Mission of Accelerating Health Equity
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….
Inaugural ERSAP Prize Awarded to Pat Garcia-Gonzalez
Estoril, Portugal– In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize. The International CML Foundation awarded our….
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.Dismiss
